Value of spleen volume in predicting portal hypertensive gastropathy and its severity in patients with liver cirrhosis

Zhiqiang ZHANG; Wei CHEN; Bo LIU

doi:10.3969/j.issn.1001-5256.2023.04.013

Volume 39 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(4): 826-833

PDF( 2045 KB)

Value of spleen volume in predicting portal hypertensive gastropathy and its severity in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2023.04.013

Department of Gastroenterology, Xiangyang No. 1 People's Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei 441000, China

Research funding:

Hubei Provincial Natural Science Foundation Project (2018CFB619)

More Information

Corresponding author: CHEN Wei, chenweiyf@163.com (ORCID: 0000-0002-6985-4595)
Received Date: 2022-09-17
Accepted Date: 2022-10-20
Published Date: 2023-04-20

Abstract

Abstract

Objective To investigate the value of spleen volume (SV) in predicting portal hypertensive gastropathy (PHG) and severe PHG in patients with liver cirrhosis. Methods A retrospective analysis was performed for the clinical data of 168 patients with liver cirrhosis who were admitted to Xiangyang No.1 People's Hospistal Affiliated to Hubei University of Medicine from January 2018 to August 2022, and with the results of gastroscopy as the gold standard, these patients were divided into non-PHG group with 115 patients and PHG group with 53 patients; the PHG group was further divided into mild PHG group with 26 patients and severe PHG group with 27 patients. All patients underwent electronic gastroscopy, abdominal magnetic resonance imaging, and serological examination to obtain related indices and parameters. The group t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. A multivariate Logistic regression analysis was used to screen out the independent risk factors for PHG and severe PHG, and the receiver operating characteristic (ROC) curve was used to compare the predictive value of related indices or parameters. The area under the Roccurve is compared using Delong test. Results The univariate analysis showed that there were significant differences between the PHG group and the non-PHG group in sex, presence or absence of ascites, hemoglobin (Hb), platelet count (PLT), aspartate aminotransferase, total bilirubin, albumin (Alb), prothrombin time, international normalized ratio, Child-Pugh class, FIB-4 score, King score, Lok score, spleen diameter (SD), SV, platelet count/spleen diameter ratio (PSDR), and platelet count/spleen volume ratio (PSVR) (all P < 0.05), and there were significant differences in Hb, PLT, Alb, SD, SV, PSDR, and PSVR between the mild PHG group and the severe PHG group (all P < 0.05). The multivariate Logistic regression analysis showed that FIB-4 score (odds ratio [OR]=1.280, 95% confidence interval [CI]: 1.009-1.625, P < 0.05) and SV (OR=1.007, 95% CI: 1.001-1.013, P < 0.05) were independent risk factors for PHG, and SV (OR=0.990, 95% CI: 0.980-1.000, P < 0.05) was an independent influencing factor for severe PHG. The ROC curve analysis showed that in predicting PHG, SV had a larger area under the ROC curve (AUC) than FIB-4 score (0.884 vs 0.825, P < 0.05), with a sensitivity of 0.774 and a specificity of 0.870 at the optimal cut-off value of 406.82; in predicting the onset of severe PHG, SV had an AUC of 0.782, with a sensitivity of 0.593 and a specificity of 0.962 at the optimal cut-off value of 714.63. Conclusion SV has a good value in predicting the onset of PHG and severe PHG.
- Liver Cirrhosis,
- Portal Hypertensive Gastropathy,
- Forecasting

FullText(HTML)

References(22)

References

[1]	LIU XJ, CHEN MK. Research advances in portal hypertensive gastropathy[J]. Chin J Dig Endosc, 2020, 37(10): 762-765. DOI: 10.3760/cma.j.cn321463-20191014-00688. 刘小娇, 陈明锴. 门脉高压性胃病研究进展[J]. 中华消化内镜杂志, 2020, 37(10): 762-765. DOI: 10.3760/cma.j.cn321463-20191014-00688.
[2]	ROCKEY DC. An update: Portal hypertensive gastropathy and colopathy[J]. Clin Liver Dis, 2019, 23(4): 643-658. DOI: 10.1016/j.cld.2019.07.002.
[3]	LYLES T, ELLIOTT A, ROCKEY DC. A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding[J]. J Clin Gastroenterol, 2014, 48(8): 712-720. DOI: 10.1097/MCG.0000000000000014.
[4]	WANG WS, CHEN DF, WEN LZ. Highlights in portal hypertensive gastropathy[J]. J Prac Hepatol, 2019, 22(4): 601-604. DOI: 10.3969/j.issn.1672-5069.2019.04.038. 王文生, 陈东风, 文良志. 门脉高压性胃病临床研究进展[J]. 实用肝脏病杂志, 2019, 22(4): 601-604. DOI: 10.3969/j.issn.1672-5069.2019.04.038.
[5]	AMER IF, EL SHENNAWY EM, EL BATEA H, et al. Accuracy of noninvasive tests in the prediction of portal hypertensive gastropathy in Egyptian patients with cirrhosis[J]. JGH Open, 2021, 5(2): 286-293. DOI: 10.1002/jgh3.12486.
[6]	EL-KALLA F, MANSOUR L, KOBTAN A, et al. Blood ammonia level correlates with severity of cirrhotic portal hypertensive gastropathy[J]. Gastroenterol Res Pract, 2018, 2018: 9067583. DOI: 10.1155/2018/9067583.
[7]	NISHINO K, KAWANAKA M, MANABE N, et al. Portal hypertensive gastropathy in liver cirrhosis: Prevalence, natural history, and risk factors[J]. Intern Med, 2022, 61(5): 605-613. DOI: 10.2169/internalmedicine.7943-21.
[8]	MIN YW, BAE SY, GWAK GY, et al. A clinical predictor of varices and portal hypertensive gastropathy in patients with chronic liver disease[J]. Clin Mol Hepatol, 2012, 18(2): 178-184. DOI: 10.3350/cmh.2012.18.2.178.
[9]	YU S, CHEN W, JIANG Z. Platelet count/spleen volume ratio has a good predictive value for esophageal varices in patients with hepatitis B liver cirrhosis[J]. PLoS One, 2021, 16(12): e0260774. DOI: 10.1371/journal.pone.0260774.
[10]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[11]	DE FRANCHIS R. Updating consensus in portal hypertension: report of the Baveno Ⅲ Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension[J]. J Hepatol, 2000, 33(5): 846-852. DOI: 10.1016/s0168-8278(00)80320-7.
[12]	BADRAN DH, KALBOUNEH HM, AL-HADIDI MT, et al. Ultrasonographic assessment of splenic volume and its correlation with body parameters in a Jordanian population[J]. Saudi Med J, 2015, 36(8): 967-972. DOI: 10.15537/smj.2015.8.11809.
[13]	MOROZOV SV, IZRANOV VA. Methods of ultrasound spleen morphometry[J]. J Ultrasound Med, 2022, 41(9): 2123-2133. DOI: 10.1002/jum.15901.
[14]	LI Y, WANG ZH, LI PP, et al. 3D visualization technology for measuring the spleen volume of normal Chinese adult[J]. J Hepatobiliary Surg, 2018, 26(5): 340-343. DOI: 10.3969/j.issn.1006-4761.2018.05.007. 李曜, 王志恒, 李鹏鹏, 等. 三维可视化技术测定中国正常成人脾脏体积的研究[J]. 肝胆外科杂志, 2018, 26(5): 340-343. DOI: 10.3969/j.issn.1006-4761.2018.05.007.
[15]	DE FRANCHIS R. Evolving consensus in portal hypertension. Report of the Baveno Ⅳ consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol, 2005, 43(1): 167-176. DOI: 10.1016/j.jhep.2005.05.009.
[16]	CHEN SY, LIN QY, HUANG XQ. Studies on diagnosis and pathogenesis of portal hypertensive gastropathy[J]. J Diagn Concepts Pract, 2016, 15(5): 451-454. DOI: 10.16150/j.1671-2870.2016.05.003. 陈世耀, 林秋燕, 黄晓铨. 门静脉高压性胃病的诊断及发病机制研究[J]. 诊断学理论与实践, 2016, 15(5): 451-454. DOI: 10.16150/j.1671-2870.2016.05.003.
[17]	DE FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[18]	SALEEM K, BAIG FA, NIDA M, et al. Correlation between severity of portal hypertensive gastropathy and size of oesophageal varices in cirrhotic hepatitis-C patients[J]. J Ayub Med Coll Abbottabad, 2018, 30(1): 54-57.
[19]	SIMBRUNNER B, BEER A, WÖRAN K, et al. Portal hypertensive gastropathy is associated with iron deficiency anemia[J]. Wien Klin Wochenschr, 2020, 132(1-2): 1-11. DOI: 10.1007/s00508-019-01593-w.
[20]	SUN DY. Prediction of FIB-4、Lok and King score measurement for esophageal varices in cirrhosis[D]. Hefei: Anhui Medical University, 2021. 孙迪一. FIB-4、Lok和King评分对肝硬化食管静脉曲张的预测价值[D]. 合肥: 安徽医科大学, 2021.
[21]	MANDHWANI R, HANIF FM, UL HAQUE MM, et al. Noninvasive clinical predictors of portal hypertensive gastropathy in patients with liver cirrhosis[J]. J Transl Int Med, 2017, 5(3): 169-173. DOI: 10.1515/jtim-2017-0025.
[22]	JIANG A, LI ZF. Common causes and treatment strategies of hyperslenism[J/OL]. Chin J Hepat Surg (Electronic Edition), 2018, 7(2): 97-99. DOI: 10.3877/cma.j.issn.2095-3232.2018.02.003. 蒋安, 李宗芳. 脾功能亢进常见原因及治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2018, 7(2): 97-99. DOI: 10.3877/cma.j.issn.2095-3232.2018.02.003.

Relative Articles

[1]	Shanshan LIU, Xiaohui YU, Jianwei CAI. Changing trend of the disease burden of liver cirrhosis in China from 1990 to 2019[J]. Journal of Clinical Hepatology, 2024, 40(4): 726-733. doi: 10.12449/JCH240414
[2]	Huawei QIU, Tianfu LIANG, Zhi ZHONG, Xuejiao JIA, Yang JIANG. Trend and prediction of the disease burden of acute hepatitis B in China[J]. Journal of Clinical Hepatology, 2023, 39(11): 2575-2579. doi: 10.3969/j.issn.1001-5256.2023.11.010
[3]	Xiao CHENG, Jiajia WANG, Jing YANG, Rong BAI, Shijie ZHANG, Hongwei ZHANG, Xiangwei WU, Rulin MA, Xianghui ZHANG, Heng GUO, Shuxia GUO, Xinyu PENG. ZJU index and the risk of nonalcoholic fatty liver disease in the Uygur population in the rural area of Xinjiang Uygur Autonomous Region： A cohort study[J]. Journal of Clinical Hepatology, 2023, 39(11): 2588-2595. doi: 10.3969/j.issn.1001-5256.2023.11.012
[4]	Xing DAI, Ben GAO, Xinxin ZHANG, Yanyan SUN, Wentao JIANG, Jiang LI. Establishment and validation of a risk prediction model for early-stage complications after liver transplantation[J]. Journal of Clinical Hepatology, 2022, 38(2): 402-408. doi: 10.3969/j.issn.1001-5256.2022.02.027
[5]	Yiping LIU, Xinping LI, Lei CHEN, Jinju XIA, Kairong SONG, Ningyang JIA, Wanmin LIU. Accurate imaging diagnosis and recurrence prediction of hepatocellular carcinoma based on artificial intelligence[J]. Journal of Clinical Hepatology, 2022, 38(3): 521-527. doi: 10.3969/j.issn.1001-5256.2022.03.006
[6]	Guoxu FANG, Qinghua ZHANG, Yongying HUANG, Jianmin WANG, Jingfeng LIU. Application of bioinformatics in predicting the risk of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(1): 15-19. doi: 10.3969/j.issn.1001-5256.2022.01.002
[7]	Bingqi MA, Huijuan MENG, Wei ZHANG, Xiaofeng DONG, Meng WANG, Jie DOU, Yuning WU, Shiping LI. Prognostic value of several immune and inflammatory indices after curative-intent resection for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2061-2066. doi: 10.3969/j.issn.1001-5256.2022.09.021
[8]	Mingwei LI, Jian GAO, Xiangwei ZHAI, Xiangjun QIAN, Xiajie WEN, Mingjie YAO, Zhaojun DUAN, Erjiang ZHAO, Ling ZHANG, Fengmin LU. Construction and analysis of a predictive model for posthepatectomy recurrence in patients with hepatocellular carcinoma based on preoperative CXCL13 measurement[J]. Journal of Clinical Hepatology, 2021, 37(4): 823-828. doi: 10.3969/j.issn.1001-5256.2021.04.020
[9]	Wang ZheXuan, Wang EnXin, Xia DongDong, Bai Wei, Wang QiuHe, Yuan Jie, Li XiaoMei, Niu Jing, Guo WenGang, Li Kai, Yin ZhanXin, Han GuoHong. Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2020, 36(1): 113-117. doi: 10.3969/j.issn.1001-5256.2020.01.025
[10]	Wang WenSheng, Zhu GuangXi, Wen LiangZhi, Chen DongFeng. Gastroscopic manifestations of portal hypertensive gastropathy in liver cirrhosis and related factors[J]. Journal of Clinical Hepatology, 2020, 36(3): 556-560. doi: 10.3969/j.issn.1001-5256.2020.03.017
[11]	Zhang LiHang, Wang ShanJuan, Lu LunGen, Liu YanLi, Wang YiFei, Xie JinBi. Predictive value of coagulation test parameters for acute upper gastrointestinal bleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2130-2135. doi: 10.3969/j.issn.1001-5256.2018.10.014
[12]	Huang XiangJun, Wang YongHeng, Duan ShanShan, Li Lan, Sun GuoHui, Yang MeiYue, Leng DaYue, Zhang WenXing. Mechanism of action of glutamine in portal hypertensive gastropathy in rats[J]. Journal of Clinical Hepatology, 2018, 34(5): 1075-1079. doi: 10.3969/j.issn.1001-5256.2018.05.029
[13]	Yang ZongGuo, Zhang JianLiang. Pathogenesis of portal hypertensive gastropathy in cirrhotic patients and the application of antacids in treatment[J]. Journal of Clinical Hepatology, 2017, 33(11): 2218-2221. doi: 10.3969/j.issn.1001-5256.2017.11.037
[14]	Zhang HaiYue, Zhou Pei, Gong ZuoJiong. Predictive value of HBs Ag quantification in pegylated interferon therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(5): 977-980. doi: 10.3969/j.issn.1001-5256.2016.05.041
[15]	Wang WenJun, Zhao Yan, Xia DongDong, Wang EnXin, Liu Lei, Han GuoHong. Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2016, 32(6): 1139-1144. doi: 10.3969/j.issn.1001-5256.2016.06.024
[16]	Huang ShuiWen, Liu BaoRong, Chen MingSheng, Lin Chun, Zhou Rui, Yang HuiAn, Jiang XiaoYan, Pan Chen, Li DongLiang. Establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B patients treated with telbivudine[J]. Journal of Clinical Hepatology, 2016, 32(7): 1287-1291. doi: 10.3969/j.issn.1001-5256.2016.07.014
[17]	Zhang ZhiQiao, Wang GongSui, Kang KaiFu, Wu GuoBiao, Wang Peng. Analysis of high-risk groups and predictive factors for hepatic steatosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(7): 1123-1125. doi: 10.3969/j.issn.1001-5256.2015.07.030
[18]	Chen Man, Zhang Xia. Research advances in molecular prediction of recurrence and metastasis of primary liver cancer after liver transplantation[J]. Journal of Clinical Hepatology, 2014, 30(12): 1361-1365. doi: 10.3969/j.issn.1001-5256.2014.12.032
[19]	Xie YanDi, Feng Bo, Gao Yan, Wei Lai. Predictive factors for mortality in patients with alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 852-857. doi: 10.3969/j.issn.1001-5256.2013.10.013
[20]	Zhang XiaoHong, Zheng RongQin, Lu CuiRong, Chen Qing, Yang ShaoJi. Ultrasonography prediction of the portal hypertensive gastropathy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2004, 20(1): 30-31.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	高淑娟，许邵娴，崔仕元，王萍，刘贵生. 肝硬化食管胃静脉曲张患者门静脉血栓形成及内镜治疗后门脉高压性胃病加重的危险因素分析. 现代生物医学进展. 2024(15): 2939-2944 .
2.	彭金平，孙淑钦，田成斌. 能谱CT成像参数与肝硬化病情程度和肝功能的相关性及对EGVB的预测价值. 长治医学院学报. 2024(04): 293-297 .
3.	张志平，邢瑞青，陈慧昱，李静，刘家云. 血清球蛋白/胆碱酯酶（G/C）及VEGF在不同病情严重程度肝硬化门脉高压性胃病患者中的表达差异及其疾病诊断价值分析. 现代生物医学进展. 2024(18): 3442-3446 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (457) PDF downloads(51)

Value of spleen volume in predicting portal hypertensive gastropathy and its severity in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2023.04.013